| Drug Type CIK therapy | 
| Synonyms K-NK cells, K NK ID101, K-NK-ID101 | 
| Target- | 
| Action- | 
| Mechanism Immunologic cytotoxicity, Natural killer cell replacements | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhaseDiscontinuedPhase 1/2 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| COVID-19 | Phase 2 | United States  | 25 Jan 2021 | 





